We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PhaseBio

News List

Alfasigma acquires the European license for bentracimab from PhaseBio prnasia
June 22, 2021
Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc., for the commercialization of bentracimab in 49 countries across Europe and other key markets.
PhaseBio and BioVectra Enter into Supply Agreement contractpharma
March 12, 2021
PhaseBio Pharmaceuticals, a clinical-stage biotech focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra, a global contract development and manufacturing organization (CDMO), have entered a ...
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor americanpharmaceuticalreview
January 17, 2020
PhaseBio Pharmaceuticals has signed an agreement with Viamet Pharmaceuticals and its wholly-owned subsidiary, Selenity Pharmaceuticals, to acquire all of the assets and intellectual property rights related to certain novel aldosterone synthase inhibitors
PhaseBio Announces Completion of Phase 2a Trial of PB2452 americanpharmaceuticalreview
September 26, 2019
PhaseBio Pharmaceuticals announced the completion of its Phase 2a clinical trial of PB2452. Full data from the trial are planned to be presented at an upcoming medical congress.